Personalized Medicine Coalition Announces Gina Ross Murdoch as Next President and CEO
The Personalized Medicine Coalition (PMC), a 501(c)3-designated nonprofit organization supported by more than 200 businesses, patient advocacy groups, and care delivery institutions, is pleased to announce Gina Ross Murdoch, MBA, as the Coalition’s next President and CEO. Ms. Murdoch is a respected leader known for her expertise partnering with biotech, pharmaceutical, and healthcare organizations to […]
Study of Six Provider Institutions Suggests Systemic Commitment to Personalized Medicine Improves Quality of Care Provided to Patients
A new peer-reviewed study shows that institutions with higher scores on a multi-factorial assessment of personalized medicine integration are more consistently matching cancer patients with genetically guided treatment options.
PMC President Edward Abrahams to Retire Dec. 31, 2024
The Personalized Medicine Coalition announces today that its founding president, Edward Abrahams, plans to retire on December 31, 2024, after 20 years of service to the organization.
Underrepresented Community Leaders Outline How to Improve Diversity and Inclusion in Biomedical Research
PMC engaged more than 60 leaders, including 38 from historically underrepresented communities
In 2023, Personalized Medicines Topped One Third of New Drug Approvals for Fourth Year in a Row
Pace of personalized rare disease treatment approvals more than doubled, from six in 2022 to 16 in 2023
Reflecting Membership Across Health Care Spectrum, PMC Board of Directors Elects Five New Members From Multiple Business Sectors
Reflecting its membership from across the health care spectrum, PMC recently elected five new board members from multiple sectors of the health care ecosystem to help guide the future development of its educational, advocacy, and research programs.
Personalized Medicine Coalition Welcomes Rep. John Moolenaar (R-MI-02) as Co-Chair of Congressional Personalized Medicine Caucus
The Personalized Medicine Coalition (PMC) is pleased today to welcome congressman John Moolenaar (R-MI-02) as a new co-chair of the Congressional Personalized Medicine Caucus.
PMC Board of Directors Shows Cross-Sector Convening Capacity With Election of New Members From Diagnostics, Pharmaceutical, and Payer Sectors
Demonstrating PMC’s ability to convene executive leaders from across the health care spectrum, PMC today announced that its board of directors has voted to elect three new board members.
Personalized Medicines Topped 25 Percent of New Drug Approvals for Eighth Year in a Row in 2022, Accounting for 34 Percent of New Molecular Entities Approved
Personalized Medicine at FDA: The Scope & Significance of Progress in 2022 Documents Pharmaceutical Industry Shift Away from One-Size-Fits-All Drugs
JCO Precision Oncology Report Shows Diagnostic Testing-Informed Treatment Strategies Benefitting Only 36 Percent of Lung Cancer Patients With Potentially Actionable Biomarkers
Clinical Practice Gaps Likely Inhibiting Impact of Personalized Medicine